BUSINESS● LOW1h ago · Sep 9, 2026, 6:29 PM
Rezolute says late-stage trial data for lead asset remains under FDA review
Seeking Alpha Tech · north america
Rezolute reports that late-stage trial data for its primary product candidate is still undergoing review by the FDA. This indicates an ongoing regulatory process for a pharmaceutical or biotech company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS22m agoFuelCell Energy reinstated with Buy rating at Craig-Hallum on emerging data center opportunitySeeking Alpha TechBUSINESS26m agoStellantis pulls 202,000 Jeeps from US roads over safety software bugSeeking Alpha TechBUSINESS27m agoCostco continues its store growth pushSeeking Alpha TechBUSINESS33m agoHPCL-led energy fund to back deep-tech start-ups; targets to cut industry’s refining bill worth ₹1 lakh croreThe Hindu